Q2 2026 EPS Estimates for Dr. Reddy’s Laboratories Limited Lifted by Zacks Research (NYSE:RDY)

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Research analysts at Zacks Research increased their Q2 2026 EPS estimates for shares of Dr. Reddy’s Laboratories in a report issued on Wednesday, August 14th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.99 for the quarter, up from their prior estimate of $0.98. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $4.13 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q3 2026 earnings at $1.00 EPS, Q4 2026 earnings at $1.04 EPS and FY2026 earnings at $4.05 EPS.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings data on Saturday, July 27th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.10 by ($0.10). The firm had revenue of $919.80 million for the quarter, compared to analyst estimates of $861.68 million. Dr. Reddy’s Laboratories had a return on equity of 20.32% and a net margin of 19.28%.

RDY has been the topic of a number of other reports. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 16th. Barclays increased their price target on shares of Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th.

Dr. Reddy’s Laboratories Trading Up 0.5 %

Shares of RDY stock opened at $83.18 on Monday. The stock has a market cap of $13.88 billion, a P/E ratio of 20.64, a P/E/G ratio of 1.81 and a beta of 0.56. The company has a quick ratio of 1.92, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories has a fifty-two week low of $63.72 and a fifty-two week high of $84.46. The business has a fifty day simple moving average of $77.97 and a 200-day simple moving average of $74.76.

Institutional Trading of Dr. Reddy’s Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cerity Partners LLC boosted its stake in shares of Dr. Reddy’s Laboratories by 13.7% during the 4th quarter. Cerity Partners LLC now owns 12,508 shares of the company’s stock worth $870,000 after purchasing an additional 1,504 shares during the last quarter. Lindbrook Capital LLC boosted its position in Dr. Reddy’s Laboratories by 19.1% during the fourth quarter. Lindbrook Capital LLC now owns 3,519 shares of the company’s stock worth $245,000 after acquiring an additional 565 shares during the last quarter. Signaturefd LLC grew its stake in Dr. Reddy’s Laboratories by 5.1% in the 4th quarter. Signaturefd LLC now owns 21,272 shares of the company’s stock worth $1,480,000 after acquiring an additional 1,032 shares during the period. CWM LLC raised its holdings in Dr. Reddy’s Laboratories by 37.9% in the 4th quarter. CWM LLC now owns 2,174 shares of the company’s stock valued at $151,000 after acquiring an additional 598 shares during the last quarter. Finally, PDS Planning Inc lifted its stake in shares of Dr. Reddy’s Laboratories by 6.3% during the 4th quarter. PDS Planning Inc now owns 5,239 shares of the company’s stock worth $365,000 after purchasing an additional 309 shares during the period. Hedge funds and other institutional investors own 14.02% of the company’s stock.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.